Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Virus or component thereof
Reexamination Certificate
2011-07-12
2011-07-12
Salimi, Ali R. (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Virus or component thereof
C530S300000
Reexamination Certificate
active
07976848
ABSTRACT:
Synthetic DNA molecules encoding the HPV58 L1 protein are provided. Specifically, the present invention provides polynucleotides encoding HPV58 L1 protein, wherein said polynucleotides are codon-optimized for high level expression in a yeast cell. The synthetic molecules may be used to produce HPV58 virus-like particles (VLPs), and to produce vaccines and pharmaceutical compositions comprising the HPV58 VLPs. The vaccines of the present invention provide effective immunoprophylaxis against papillomavirus infection through neutralizing antibody and cell-mediated immunity and are also useful for treatment of existing HPV infections.
REFERENCES:
patent: 5821087 (1998-10-01), Lowe et al.
patent: 6159729 (2000-12-01), Hofmann et al.
patent: 7482015 (2009-01-01), Bryan et al.
patent: 2004/0121465 (2004-06-01), Robinson
patent: WO 98/34640 (1998-08-01), None
patent: WO 99/02694 (1999-01-01), None
patent: WO 00/09157 (2000-02-01), None
patent: WO 01/14416 (2001-03-01), None
patent: 01/28585 (2001-04-01), None
patent: WO 02/08435 (2002-01-01), None
patent: WO 2004/084831 (2004-10-01), None
patent: WO 2005/032586 (2005-04-01), None
Bosch, et al., “The casual relation between human papillomavirus and cervical cancer”, J. Clin. Path., vol. 55, pp. 244-265, 2002.
Breitburd, et al., “Immunization with Viruslike Particles from Cottontail Rabbit Papillomavirus (CRPV) Can Protect against Experimental CRPV Infection”, J. of Virol., vol. 69, No. 6, Jun. 1995, pp. 3959-3963.
Guo, et al., “Signals Sufficient for 3′-End Formation of Yeast mRNA”, Mol and Cell Biology, vol. 16, No. 6, pp. 2772-2776, Jun. 1996.
Heidmann, et al., “Flexibility and Interchangeability of Polyadenylation Signals inSaccharomyces cerevisiae”, Mol. and Cell Biology, vol. 14, No. 7, 1994, pp. 4633-4642.
Henikoff, et al., “Transcription Terminates in Yeast Distal to a Control Sequence”, Cell., vol. 33, Jun. 1983, pp. 607-614.
Hofmann, et al., “Sequence Determination of Human Papillomavirus Type 6a and Assembly of Virus-Like Particles inSaccharomyces cerevisiae”, Virology, vol. 209, 1995. pp. 506-518.
Jansen, et al., “Vaccination with yeast-expressed cottontail rabbit papillomavirus (CRPV) virus-like particles protects rabbits from CRPV-induced papillomavirus formation”, Vaccine, vol. 13, No. 16, 1995, pp. 1509-1514.
Kirii, et al., “Human Papillomavirus Type 58 DNA Sequence”, Virology, vol. 185, 1991, pp. 424-427.
Kotula, et al., “Evaluation of Foreign Gene Codon Optimization in Yeast: Expression of a Mouse IG Kappa Chain”, Biotechnology, vol. 9, Dec. 1991, pp. 1386-1389.
Liu, et al., “Polynucleotide viral vaccines: codon optimisation and ubiquitin conjugation enhanced prophylactic and therapeutic efficacy”, Vaccine, vol. 20, 2002, pp. 862-869.
McMurray, et al., “Biology of human papillomaviruses”, J. Exp. Path., vol. 82, 2001, pp. 15-33.
Russo, et al., “Saccharomyces cerevisiaemRNA 3′ End Forming Signals are also Involved in Transcription Termination”, Yeast, vol. 11, 1995, pp. 447-453.
Schiffman, et al., “Epidemiologic Evidence Showing That Human Papillomavirus Infection Causes Most Cervical Intraepithelial Neoplasia”, J. of National Cancer Inst., vol. 85, vol. 12, 1993, pp. 958-964.
Schiller, et al., “Papillomavirus-Like Particles: Basic and Applied Studies”, UK: Leeds Medical Information, 1996, pp. 101-112.
Schiller, et al., “Papillomavirus-Like Particle Vaccines”, J. Natl. Cancer Inst. Monographs, No. 28, 2000, pp. 50-54.
Schiller, et al., “Developing HPV virus-like particle vaccines to prevent cervical cancer: a progress report”, J. of Clin. Virology., vol. 19, 2000, pp. 67-74.
Sharp, et al., “Synonymous Codon Usage inSaccharomyces cerevisiae”, Yeast, vol. 7, 1991, pp. 657-678.
Suzich, et al., “Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas”, PNAS USA, vol. 92, Dec. 1995, pp. 11553-11557.
Thalenfeld, et al., “oli 1 Transcripts in Wild Type and in a Cytophasmic ‘Petite’ Mutant of Yeast*”, J. of Biol Chem., vol. 258, No. 23, Dec. 10, 1983, pp. 14065-14065.
Tobery, et al., “Effect of vaccine delivery system on the induction of HPV 16L1-specific humoral and cell-mediated immune responses in immunized rhesus macaques”, Vaccine, vol. 21, 2003, pp. 1539-1547.
Zaret, et al., “DNA Sequence Required for Efficient Transcription Termination in Yeast”, Cell, vol. 28, Mar. 1982, pp. 563-573.
Zaret, et al., “Mutationally Altered 3′ Ends of Yeast CYC1 mRNA Affect Transcript Stability and Translational Efficiency”, J. Mol. Biol., vol. 176, 1984, pp. 107-135.
Zhou, et al., “Papillomavirus Capsid Protein Expression Level Depends on the Match Between Codon Usage and tRNA Availability”, J. of Virol., vol. 73, No. 6, Jun. 1999, pp. 4972-4982.
Brownlow Michelle K.
Bryan Janine T.
Jansen Kathrin U.
Schultz Loren D.
Wang Xin-Min
Finnegan Alysia A.
Heber Sheldon O.
Merck Sharp & Dohme Corp.
Salimi Ali R.
LandOfFree
Optimized expression of HPV 58 L1 in yeast does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Optimized expression of HPV 58 L1 in yeast, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Optimized expression of HPV 58 L1 in yeast will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2656186